109 related articles for article (PubMed ID: 12546960)
61. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.
Kottaridis PD; Gale RE; Linch DC
Leuk Lymphoma; 2003 Jun; 44(6):905-13. PubMed ID: 12854887
[TBL] [Abstract][Full Text] [Related]
62. The expression of FMS, KIT and FLT3 in hematopoietic malignancies.
Birg F; Rosnet O; Carbuccia N; Birnbaum D
Leuk Lymphoma; 1994 Apr; 13(3-4):223-7. PubMed ID: 7519507
[TBL] [Abstract][Full Text] [Related]
63. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
64. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
Stirewalt DL; Meshinchi S; Kussick SJ; Sheets KM; Pogosova-Agadjanyan E; Willman CL; Radich JP
Br J Haematol; 2004 Feb; 124(4):481-4. PubMed ID: 14984498
[TBL] [Abstract][Full Text] [Related]
65. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
66. Receptor tyrosine kinases in normal and malignant haematopoiesis.
Reilly JT
Blood Rev; 2003 Dec; 17(4):241-8. PubMed ID: 14556779
[TBL] [Abstract][Full Text] [Related]
67. [Internal tandem duplication in the juxtamembrane domain of the Flt3 gene found in leukemias].
Yokota S; Kiyoi H
Rinsho Ketsueki; 1998 Feb; 39(2):83-5. PubMed ID: 9545804
[No Abstract] [Full Text] [Related]
68. [Pathophysiology and treatment of acute myeloid leukemia].
Naoe J
Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
[No Abstract] [Full Text] [Related]
69. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
Grandage VL; Everington T; Linch DC; Khwaja A
Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
[TBL] [Abstract][Full Text] [Related]
70. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
[TBL] [Abstract][Full Text] [Related]
71. FLT3 Inhibitors in the Treatment of AML.
Gilliland DG
Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
[No Abstract] [Full Text] [Related]
72. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
73. Pharmacogenomics suggests new treatment approach for leukaemia.
Senior K
Drug Discov Today; 2002 Aug; 7(15):791-2. PubMed ID: 12546960
[No Abstract] [Full Text] [Related]
74. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group.
Xu F; Taki T; Eguchi M; Kamada N; Ishii E; Endo M; Hayashi Y
Leukemia; 2000 May; 14(5):945-7. PubMed ID: 10803532
[No Abstract] [Full Text] [Related]
75. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
76. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
